Aukera Therapeutics qualifies for BaseLaunch funding program

The founders of the spin-off Aukera Therapeutics: Dritan Liko and Stefan Imseng. The spin-off Aukera Therapeutics, which was founded at the Biozentrum last year, has been selected for the start-up accelerator program BaseLaunch. The biotech company develops novel therapies for patients suffering from mTOR related diseases such as cancer and neurodegenerative diseases. mTOR plays a key role in cell growth control. With its qualification for the BaseLaunch Accelerator Program, Aukera Therapeutics receives funding of up to 500,000 Swiss francs as well as business development support. This includes strategic and individual advice also on legal aspects and access to BaseLaunch program infrastructure and network. "We are thrilled that our newly founded start-up has been selected to join the BaseLaunch portfolio," says Stefan Imseng, one of the two young entrepreneurs.